EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early Dexmedetomidine in Ventilated Acute Myocardial Infarction: A Target Trial Emulation Using MIMIC‐IV

Shengkai Wang, Dong Chang, Fang Peng, Yiping He

Journal of Interventional Cardiology · 2026-01 · 2026 (1)

DOI: 10.1155/joic/5946180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Interventional Cardiology, online erschienen am 09.05.2026. Verfasst von Shengkai Wang und 3 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sedation choice may influence outcomes in acute myocardial infarction (AMI) patients requiring invasive mechanical ventilation (IMV). Dexmedetomidine (DEX) provides arousable sedation with sympatholytic effects and is guideline‐endorsed, but data in ventilated AMI patients—particularly for intermediate‐term mortality—are limited.

Objective

To evaluate the association between early DEX initiation and 90‐day all‐cause mortality among AMI patients starting IMV. Design, Setting, and Participants Retrospective cohort and target trial emulation using the MIMIC‐IV database. Adults with AMI admitted to the ICU who initiated their first IMV episode within 7 days were included. Time zero (t0) was the start of IMV. Admissions involving cardiac surgery procedures were excluded. The final analytic cohort comprised 2024 patients (266 received early DEX). Exposure Early DEX, defined as initiation within 24 h after t0, versus no early DEX. Main Outcomes and Measures The primary outcome was 90‐day all‐cause mortality from t0. The secondary outcome was ventilator‐free days to Day 28 (VFD‐28). The primary analysis used a covariate‐balancing propensity score (CBPS) with stabilized inverse probability weights and a weighted Cox model with robust, patient‐clustered standard errors. Prespecified sensitivity analyses included IPTW‐Cox with weight truncation, targeted maximum likelihood estimation (TMLE), 30‐day mortality, and exclusion of out‐of‐hospital cardiac arrest (OHCA).

Results

Among 2024 eligible patients, early DEX use was associated with a lower hazard of 90‐day mortality (HR 0.572; 95% CI 0.441–0.742; p < 0.001) and more ventilator‐free days (mean difference 4.94 days; 95% CI 3.49–6.40; p < 0.001). Sensitivity analyses were directionally consistent, and postweighting covariate balance met prespecified targets.

Conclusions

In this target trial emulation of AMI patients requiring IMV, early initiation of DEX within 24 h was associated with lower 90‐day mortality and more ventilator‐free days. Findings were consistent across multiple analytic approaches and cohort restrictions but remain observational and should not be interpreted as establishing causality. Prospective studies are warranted to confirm causality, define safety boundaries, and guide patient selection.

Zitieren

APA

Wang, S., Chang, D., Peng, F., & He, Y. (2026). Early Dexmedetomidine in Ventilated Acute Myocardial Infarction: A Target Trial Emulation Using MIMIC‐IV. Journal of Interventional Cardiology, 2026(1). https://doi.org/10.1155/joic/5946180

Vancouver

Wang S, Chang D, Peng F, He Y. Early Dexmedetomidine in Ventilated Acute Myocardial Infarction: A Target Trial Emulation Using MIMIC‐IV. Journal of Interventional Cardiology. 2026;2026(1). doi:10.1155/joic/5946180

BibTeX
@article{Wang2026,
  author = {Wang, Shengkai and Chang, Dong and Peng, Fang and He, Yiping},
  title = {Early Dexmedetomidine in Ventilated Acute Myocardial Infarction: A Target Trial Emulation Using MIMIC‐IV},
  journal = {Journal of Interventional Cardiology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/joic/5946180}
}
Kostenlos starten →